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Aleurone flour increases red-cell folate and lowers plasma homocyst(e)ine
substantially in man
Michael Fenech*, Manny Noakes, Peter Clifton and David Topping
CSIRO Health Sciences and Nutrition, PO Box 10041, Gouger Street, Adelaide BC, SA 5000, Australia
(Received 17 June 2004 – Revised 31 October 2004 – Accepted 19 November 2004)
Aleurone flour (ALF) is a rich source of natural folate (.500mg/100 g wet weight). Our objective was to establish whether intake of ALF in man can
significantly improve folate status and reduce plasma homocyst(e)ine. We performed a randomised, controlled intervention, of 16 weeks duration, in
free-living healthy individuals (mean age 46–52 years). Participants were assigned to one of three groups: ALF, 175 g bread made with ALF and placebo
tablet each day; PCS, 175 g bread made with pericarp seed coat (PCS) flour and placebo tablet each day (low-folate control); or FA, 175 g bread made with
PCS flour and tablet containing 640mg folic acid each day (high-folate control). The daily folate intake contributed by the bread and tablet was 233mg in the
PCS group, 615mg in the ALF group and 819mg in the FA group. The number of participants completing all phases of the PCS, ALF and FA interventions
was twenty-five, twenty-five and eighteen, respectively. Plasma and red-cell folate increased significantly (P,0·0001) and plasma homocyst(e)ine decreased
significantly (P,0·0001) in the ALF and FA groups only. Plasma folate and red-cell folate in the ALF group (mean, 95 % CI) increased from baseline
values of 12·9 (9·9, 15·7) nmol/l and 509 (434, 584) nmol/l to 27·1 (22·5, 31·7) nmol/l and 768 (676, 860) nmol/l, respectively. Plasma homocyst(e)ine
in the ALF group decreased from 9·1 (8·2, 10·0)mmol/l at baseline to 6·8 (6·2, 7·5)mmol/l after 16 weeks. In conclusion, moderate dietary intake of
ALF can increase red-cell folate and decrease plasma homocyst(e)ine substantially.
Aleurone: Bread: Folate: Folic acid: Homocyst(e)ine: Man
Inadequate intake of folate is recognised as a risk factor for neural
tube defects in the developing fetus (MRC Vitamin Study
Research Group, 1991; Czeizel & Dudas, 1992) and is an import-
ant cause of anaemia (Wagner, 1995). Furthermore, chromosome
aberrations in cells, a risk factor for cancer (Blount et al. 1997;
Bonassi et al. 2000; Fenech, 2001), and plasma homocyst(e)ine,
a risk factor for CVD (Kang et al. 1992; Boushey et al. 1995;
Law, 2000; Rasmussen et al. 2000), are both increased when
blood folate levels are sub-optimal. Consequently, the RDA for
folate has been revised to a level of 400mg/d (Cuskelly et al.
1996; Daly et al. 1997; Stevenson et al. 2000). It has also been
suggested that a higher intake of folate may be required in
those individuals who cannot metabolise folate efficiently due
to mutations in key genes such as methylenetetrahydrofolate
reductase required for the synthesis of methyltetrahydrofolate,
which acts as a methyl donor to homocyst(e)ine in the synthesis
of methionine (Molloy et al. 1997; Rosenberg & Rosenberg,
1998).
Supplementation with folic acid (FA) can effectively raise
blood folate, minimise the risk for neural tube defects and
lower plasma homocyst(e)ine levels (Cuskelly et al. 1996; Daly
et al. 1997; Molloy et al. 1997; Chambers et al. 2000; Rasmussen
et al. 2000; Stevenson et al. 2000). However, the evidence that a
similar outcome can be reliably obtained by natural sources from
foods remains equivocal. Early studies had suggested that folate
from vegetables and cereals may not be as bioavailable as folic
acid given as a supplement (Gregory, 1995; Cuskelly et al.
1996). More recent studies have shown that the bioavailability
of folate from fruits and vegetables as well as aleurone flour
(ALF) may be .60 % of that for folic acid from a tablet (Brouwer
et al. 1999; Fenech et al. 1999).
Our research has focused on the bioavailability of folate from
the aleurone layer of the wheat grain. The aleurone layer of
cells provides the key micronutrients for growth of the embryo
during germination (Saxelby & Venn-Brown, 1980) and is par-
ticularly noted for its high level of folate (.500mg/100 g wet
weight; Fenech et al. 1999). Using a novel milling technology
it has become economically viable to isolate the aleurone layer
of cells from the pericarp seed coat (PCS) and the starchy endo-
sperm to produce ALF (Stenvert, 1995, 1997; Fig. 1). ALF is now
available on international markets and is being used for making
breads that are naturally rich in folate.
Our initial studies showed that the increase in plasma folate
over the 7 h period following ingestion of 100 g ALF was more
than fourfold greater than that for 100 g wheat bran and equival-
ent to that observed following intake of 500mg folic acid taken
with 100 g wheat bran (Fenech et al. 1999). We therefore per-
formed a long-term (16 weeks), randomised, controlled interven-
tion to verify the incremental effect of ALF ingestion on plasma
folate concentration and determine whether moderate ALF intake
can also substantially increase red-cell folate and reduce plasma
homocyst(e)ine to an extent that is close to the maximum effect
produced by taking a daily supplement containing .500mg
folic acid.
* Corresponding author: Dr Michael Fenech, fax þ61 (08) 8303 8899, email michael.fenech@csiro.au
Abbreviations: ALF, aleurone flour; FA, folic acid; PCS, pericarp seed coat.
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Materials and methods
Study population
Volunteers were recruited by advertising the study in local news-
papers without providing payment for participation. A total of 235
volunteers (mainly Caucasian) aged 20–70 years were screened
initially for plasma homocyst(e)ine, red-cell folate and plasma
vitamin B12 concentrations. We included individuals with
plasma homocyst(e)ine above the 50th percentile (median) and
red-cell folate below the 50th percentile (median). We excluded
volunteers with low levels of plasma vitamin B12 (,150 pmol/
l), and/or who were taking folate and vitamin B12 supplements
above the Australian recommended dietary intake levels (i.e.
.200mg folic acid/d, .2mg vitamin B12/d), and/or who were
epileptic and on anticonvulsant therapy, and/or who had a past
or present history of cancer or pernicious anaemia. Of the initial
235 volunteers screened, only seventy-nine met the selection cri-
teria described above and these individuals were invited to par-
ticipate in the study. The purpose of the study and their
involvement was explained to the volunteers in a series of infor-
mation sessions. Informed consent was subsequently obtained
from all subjects. Three volunteers withdrew before the start of
the intervention and sixty-eight completed every phase of the
intervention. Withdrawal and lack of attendance to all appoint-
ments was due to travel difficulties, change in home address
and other unexpected changes in personal schedules.
Study design
The study was designed as a randomised, controlled intervention
in a free-living, middle-aged healthy population, comparing the
effect of a high-folate bread made with ALF with that of a low-
folate bread made with PCS flour and that of a folic acid tablet
given with the low-folate PCS bread. The appearance and texture
of the ALF and PCS breads were similar. Volunteers were
assigned to the three dietary groups using a randomised block
design based on screening plasma homocyst(e)ine concentration.
The dietary groups were: ALF group, ALF bread plus placebo
tablet; PCS group, PCS bread plus placebo tablet (low-folate con-
trol group); and FA group, PCS bread plus folic acid tablet (high-
folate control group).
The breads (supplied by Goodman Fielder Milling and Baking
Pty Ltd, Summerhill, Sydney, NSW, Australia) were balanced for
starch and fibre content and were kept stored frozen at 2208C
until required. ALF bread contained 38·5 g ALF and 20·1 g
white flour per 100 g (wet weight) in comparison to PCS bread,
which contained 11·3 g PCS flour and 57·6 g white flour per
100 g (wet weight). The folate content, expressed as the mean
of triplicate measurements, of ALF bread and PCS bread was
340 (SEM 9) mg/100 g (wet weight) and 112 (SEM 15) mg/100 g
(wet weight), respectively. The folate content of PCS flour and
white flour relative to ALF was 24 % and 3 %, respectively.
Using the latter figures and the relative amounts of different
types of flour in the ALF and PCS breads, we estimated that in
ALF bread 98·5 % of the folate originated from ALF and 1·5 %
from white flour; and in PCS bread 61·8 % of the folate content
was due to the PCS flour and 38·2 % was contributed by white
flour. The ALF and PCS breads were cut into 70 g (wet weight)
slices, which contained approximately 238mg and 78mg folate
per slice, respectively. ALF and PCS breads were similar with
regard to protein content (10·5, 7·8 g/100 g wet weight), starch
(26·6, 31·0 g/100 g wet weight), total dietary fibre (7·2, 7·0 g/
100 g wet weight) and sugars (4·2, 4·3 g/100 g wet weight).
Folic acid (mean of duplicate measurements) in the folic acid
tablet and the placebo tablet was 640mg and 26mg, respectively.
Tablets were supplied by Blackmore’s Ltd (Balgowlah, NSW,
Australia). Breads and tablets were provided each fortnight to vol-
unteers who kept the bread frozen until use.
Volunteers were requested to eat 2·5 slices (175 g wet weight)
of the provided bread per day and ingest one tablet per day of the
tablets provided. They were also asked to keep to their customary
diet and to refrain from ingesting folic acid supplements or foods
that were supplemented with folic acid. The dose of the folic acid
supplement in the tablet was chosen to produce a maximum effect
on lowering of plasma homocyst(e)ine (Rydlewicz et al. 2002;
van Oort et al. 2003). The level of ALF or PCS flour in bread
and the amount of bread eaten per day were the maximum poss-
ible without compromising palatability and compliance during the
intervention. We chose PCS bread as the low-folate control to bal-
ance for starch and fibre content and thus minimise the possible
effect of differences in bowel fermentation on folate status
(Rong et al. 1991). The low level of folic acid in the placebo
tablet was unintended and caused by contamination with folic
acid during formulation of the tablets.
The intervention was of 16 weeks’ duration to maximise the
detection of red-cell folate changes because red blood cells
have a life-span of 120 days (Cooper & Jandl, 1972). Blood
samples were collected just before the start of the intervention
and at 28 d intervals thereafter. Red-cell and plasma folate,
plasma homocyst(e)ine and vitamin B12 were measured at each
time point.
The study protocol was approved by the Human Ethics Experi-
mentation Committee of CSIRO Health Sciences and Nutrition
and complied with the Helsinki Declaration of 1975 as revised
in 1983 (Helsinki Declaration, 1996).
Measurement of dietary folate intake and compliance
During the course of the intervention volunteers were required to
keep a daily record of the consumption of the following items:
Fig. 1. A schematic diagram showing the key steps in the isolation of white
flour, pericarp seed coat flour and aleurone flour.
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number of slices of bread; number of tablets; number of servings
of fruit juice, dried fruit, canned fruit, cooked fruit and fresh
fruits; number of servings of vegetable juice, vegetable soup,
cooked vegetables, salad vegetables and potatoes; number of ser-
vings of breakfast cereal including breakfast cereal with added
folic acid; and number of servings of flesh foods. The results of
this record were used to estimate the contribution to folate
intake of other foods relative to the bread and tablet provided
and to obtain a measure of compliance. Folate intake estimates
were based on published food composition tables (Holland et al.
1995) as well as values obtained by analysis in the case of the test
breads and tablets.
Analysis of breads and tablets
Total starch was analysed using the method of McCleary et al.
(1994). Total dietary fibre was determined by the gravimetric
method of Prosky et al. (1985). Fat content measurement was
done according to the method of Daugherty & Lento (1983).
The total nitrogen level was determined using the method of
Kirsten & Hesselius (1983) on a Carlo Erba nitrogen analyser
(Carlo Erba Strumentazione, Rodano, Milan, Italy). Free sugars
were extracted with 80 % aqueous methanol according to the
method of Theander & Westerlund (1986), and then quantified
by HPLC using acetonitrile–water 75:25 as the mobile phase, a
polyamine-bonded polymeric gel column (Advanced Separation
Technologies Inc., Whippany, NJ, USA) and a refractive index
detector (GBC Scientific Equipment, Dandenong, VIC, Australia).
Ash was measured by igniting the samples in pre-weighed boro-
silicate glass crucibles in a muffle furnace at 5158C for 12 h and
then cooling in a desiccator prior to weighing; the percentage ash
weight was calculated by difference. Folic acid in tablets was
measured in three separate random samples of ten tablets,
which were finely ground prior to analysis, using a modification
of the standard Association of Official Analytical Chemists
microbiological assay (AOAC International, 1996; Scheelings,
1996; Fenech et al. 1999). Folate in three separate, finely
ground bread samples (mesh size ,0·5 mm) was measured
using the tri-enzyme method (Rader et al. 1998) without heating
and centrifugation before tri-enzyme extraction using digestion
with protease, a-amylase and chicken pancreas conjugase as
described previously (Tamura et al. 1997; Shrestha et al. 2000).
CV for duplicate samples was , 8 % for all analyses.
Measurement of plasma folate, red cell folate and plasma total
homocyst(e)ine
Volunteers donated their blood samples between 08.00 and 11.00
hours, after an overnight fast and before having breakfast, to
minimise possible confounding effects by dietary metabolites
and diurnal variation. Plasma from the EDTA blood sample and
whole blood haemolysate (prepared by mixing 100ml fresh
EDTA blood with 1 ml of a fresh solution of 0·4 % ascorbic
acid) were snap-frozen in liquid nitrogen and stored at 2808C
until analysed. Plasma folate and vitamin B12 and red-cell
folate (haemolysate) were analysed in duplicate using a radio-
immunoassay kit (Quantaphase II; Bio-Rad, Hercules, CA,
USA). Haematocrits of fresh blood samples were also measured
in each case to enable the appropriate calculation of red-cell
folate from the results obtained for the haemolysate.
Analysis of plasma homocyst(e)ine was performed according to
the method of Vester & Rasmussen (1991). Briefly, blood
samples for homocyst(e)ine were collected in EDTA tubes and
placed on ice, and plasma was separated within 30 min of collec-
tion, snap-frozen in liquid nitrogen and stored at 2808C until ana-
lysed. On the day of analysis, plasma was thawed, reduced with
tri-n-butylphosphine, proteins were precipitated and the sample
derivatised with ammonium 7-fluoribenzo-2-oxa-1,3-diazole-
4-sulfonate. Homocyst(e)ine was detected by HPLC using fluor-
escence detection (DP800 chromatography system; GBC
Scientific Equipment). Mercaptopropionylglycine was used as
an internal standard and the calibration curve was based on
measurements with human plasma to which known amounts of
unbound homocyst(e)ine were added.
To minimise experimental variation, the assays were performed
using a single batch of each reagent throughout the intervention
and all the samples for each individual and their matching controls
were analysed on the same day in the same assay run. All biochemi-
cal assays were performed in duplicate. The intra-assay CV for the
measurement of folate, vitamin B12 and homocyst(e)ine was 3·73 %
(SD 0·68), 2·64 % (SD 0·45) and 3·86 % (SD 0·77), respectively. Each
assay was performed by a single person and the samples were coded,
so that the operator had no knowledge about the treatment group to
which they belonged; the codes of the samples were revealed only
after the assays were completed.
Statistical analysis
The intended aim was to have a minimum of twenty-five volunteers
in each group completing the intervention, which would provide,
based on standard deviation values from the screening data, 85 %
power to detect a change in homocyst(e)ine of 2·37mmol/l and
99 % power to detect a difference in red-cell folate of 200 nmol/l
with P,0·05. When appropriate, data were log-transformed to nor-
malise distribution prior to statistical analysis. Comparisons
between groups were performed using one-way ANOVA and the
post hoc Bonferroni multiple-comparison test. To compare differ-
ences in response between groups at 16 weeks, we calculated the
percentage difference relative to baseline values after adjustment
of the data at 16 weeks for baseline values as recommended by Vick-
ers & Altman (2001). Correlation analysis between two sets of data
was performed using Pearson’s test. Values of P,0·05 were con-
sidered to be statistically significant. Prism 4.0 (GraphPad Inc.,
San Diego, CA, USA) and CSS Statistica (Statsoft Inc., Tulsa,
OK, USA) software were used to obtain these estimates.
Results
Profile of participants who completed the intervention
The number of participants who completed every phase of the
intervention was twenty-five, twenty-five and eighteen for the
ALF, PCS and FA groups, respectively. Their profile, at screen-
ing, is summarised in Table 1. Age, BMI and biochemical par-
ameters were well matched and not significantly different
between groups. Mean plasma homocyst(e)ine ranged between
8·6 and 8·9mmol/l and mean red-cell folate ranged between 457
and 471 nmol/l. Gender ratios were similar in the ALF and PCS
groups (48 % and 52 % males, respectively) but the proportion
of males was lower in the FA group (28 % males).
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Dietary record and compliance data
The dietary record data (Table 2) showed high compliance in
tablet consumption in all groups (.95 %). Mean consumption
rate of the supplied breads averaged between 2·4 and 2·5 slices
per day (i.e. 167–178 g wet weight), and consumption of fruit,
vegetables, breakfast cereals and flesh foods was similar between
groups.
Folate intake
Using the dietary record and compliance data it was possible to
estimate consumption of folate in the study groups (Table 3).
Total daily folate intake in the ALF group (836mg) was signifi-
cantly lower than that in the FA group (1059mg) and significantly
greater than that in the PCS group (436mg; ANOVA, P,0·0001).
Folate from ALF bread contributed 70 % of the folate intake in
the ALF group. It was evident that dietary sources other than
the supplied bread and tablets provided a significant proportion
of the dietary folate (between 213 and 239mg of the total) in
the three groups.
Estimated folate intake from the dietary record was significantly
correlated with plasma homocyst(e)ine (r 20·55, P,0·0001),
plasma folate (r 0·69, P,0·0001) and red-cell folate (r 0·64,
P,0·0001) measured at the end of the intervention. The corre-
lation factors with estimated folate intake (plasma homocyst(e)ine,
r 2 0·43; plasma folate, r 0·56; red-cell folate, r 0·47) were
reduced slightly but remained significant (P,0·001) when dietary
record data for the FA group were removed.
Plasma and red-cell folate
There was no change in plasma folate levels in the PCS group
during the course of the intervention. However, significant incre-
ments in plasma folate occurred in the ALF and FA groups at 4
weeks and subsequent sampling times, with mean plasma folate
levels increasing from 12·9 and 17·5 nmol/l at baseline to 27·1
and 40·1 nmol/l, respectively, at 16 weeks (Table 4). The percen-
tage change in plasma folate at 16 weeks (adjusted for baseline
level; Fig. 2(a)) in the ALF and FA groups was significantly ele-
vated relative to that in the PCS group (P,0·0001). Moreover,
the increment observed in the FA group was 1·7 times greater
than in the ALF group (P,0·0001).
There was a 16 % increment in red-cell folate at 16 weeks
(relative to baseline) in the PCS group during the course of the
intervention (ANOVA, P¼0·081). The increments in red-cell
folate in the ALF and FA groups were much greater, achieving
significant increases by 12 weeks of 50·9 % and 79·2 % relative
to baseline, respectively (Table 4 and Fig. 2(b)). The increment
differences observed at 16 weeks between groups were statisti-
cally significant for all comparisons (Fig. 2(b)). There were no
significant changes in haematocrit and vitamin B12 in any of
the groups (data not shown).
Table 1. Profile, at screening, of participants who completed all stages of the intervention in each dietary group*
(Values are arithmetic means and their 95 % CI or percentages†)
PCS group (n 25) ALF group (n 25) FA group (n 18)
Mean 95 % CI Mean 95 % CI Mean 95 % CI
Plasma folate (nmol/l) 10·7 8·5, 12·9 12·7 9·7, 15·6 13·3 10·9, 15·7
Red-cell folate (nmol/l) 457 409, 506 467 412, 522 471 399, 542
Plasma homocyst(e)ine (mmol/l) 8·9 8·2, 9·7 8·9 7·9, 9·9 8·6 7·8, 9·5
Plasma vitamin B12 (pmol/l) 323 281, 366 287 255, 318 267 230, 305
Haematocrit (%) 42·2 40·7, 43·8 43·0 41·6, 44·5 42·1 40·6, 43·6
Age (years) 51·8 47·8, 55·8 50·2 46·2, 54·3 46·3 41·3, 51·4
BMI (kg/m2) 27·7 25·6, 29·9 26·0 24·5, 27·5 25·9 23·8, 28·1
Gender (% males) 52 48 28
Smokers (%) 8 8 6
* Treatment groups: PCS group, subjects received bread made with pericarp seed coat (PCS) flour plus placebo tablet (low-folate control);
ALF group, subjects received bread made with aleurone flour (ALF) plus placebo tablet; FA group, subjects received PCS bread plus folic
acid tablet (high-folate control).
† Values are not significantly different between groups.
Table 2. Compliance and daily dietary intake data
(Values are arithmetic means and their 95 % CI)
PCS group (n 25) ALF group (n 25) FA group (n 18)
Mean 95 % CI Mean 95 % CI Mean 95 % CI P (ANOVA)
Tablets (n/d) 0·96 0·94, 0·99 0·97 0·94, 1·00 0·98 0·97, 1·00 0·4881
Bread (slices/d) 2·5 2·3, 2·8 2·5 2·2, 2·7 2·4 2·1, 2·6 0·6261
Fruit (servings/d) 1·8 1·4, 2·3 2·0 1·5, 2·4 2·1 1·5, 2·7 0·9333
Vegetables (servings/d) 3·1 2·5, 3·7 3·2 2·6, 3·8 3·6 2·9, 4·2 0·3786
Breakfast cereal (servings/d) 0·5 0·2, 0·8 0·4 0·2, 0·6 0·6 0·2, 0·9 0·7192
Flesh† food (servings/d) 1·2 0·9, 1·4 1·0 0·9, 1·2 1·3 0·9, 1·6 0·3184
Treatment groups: PCS group, subjects received bread made with pericarp seed coat (PCS) flour plus placebo tablet (low-folate control); ALF group, subjects
received bread made with aleurone flour (ALF) plus placebo tablet; FA group, subjects received PCS bread plus folic acid tablet (high-folate control).
† Meat, chicken or fish.
M. Fenech et al.356
Plasma homocyst(e)ine
Significant reductions in plasma homocyst(e)ine were observed in
the ALF group and the FA group only. The maximum homocys-
t(e)ine reduction in the ALF group from 9·1mmol/l (at baseline)
to 6·8mmol/l was observed at 8 weeks. In the FA group homocys-
t(e)ine was reduced from 8·1mmol/l (at baseline) to a minimum of
6·0mmol/l at 16 weeks (Table 4). A comparison of change in
plasma homocyst(e)ine (adjusted for baseline level) showed that
there was no significant difference between the ALF group and
the FA group at 16 weeks (Fig. 2(c)). Plasma homocyst(e)ine
was negatively correlated with plasma folate at all stages of the
study (r 2 0·29 to 20·42, P,0·01); negatively correlated with
red-cell folate only at weeks 8, 12 and 16 (r 2 0·22 to 20·32,
P,0·05); negatively correlated with plasma vitamin B12 at
screening (r 2 0·416, P,0·001) and at the start and end of the
intervention (r 2 0·241 and 20·267, respectively, P,0·05);
and positively correlated with BMI at all stages of the study
(r 0·248 to 0·353, P,0·05).
Discussion
Natural dietary sources of folate remain important for preventing
folate deficiency in those countries where staple food fortification
with folic acid is not mandatory (e.g. Australia) or prohibited (e.g.
The Netherlands). There is some justifiable concern that natural
dietary sources may not provide an adequately large and reliable
intake of folate to prevent developmental and degenerative dis-
eases caused by sub-optimal intakes, because of uncertainty
over the folate content of foods as well as the bioavailability
(absorbed fraction that can be used metabolically) and bioefficacy
(relative effect on a functional parameter such as prevention of
Table 3. Daily folate intake (mg) from supplied tablets and bread and other dietary sources during the intervention
(Values are arithmetic means and their 95 % CI)
PCS group (n 25) ALF group (n 25) FA group (n 18)
Mean 95 % CI Mean 95 % CI Mean 95 % CI P (ANOVA)
Tablets† 25 24, 26a 25 25, 26a 633 625, 641b ,0·0001
Bread 198 182, 215a 590 533, 647b 186 167, 206a ,0·0001
Other dietary sources 213 175, 250 220 188, 253 239 203, 275 0·4749
Total 436 393, 478a 836 769, 903b 1059 1028, 1090c ,0·0001
Treatment groups: PCS group, subjects received bread made with pericarp seed coat (PCS) flour plus placebo tablet (low-folate control); ALF group, subjects received
bread made with aleurone flour (ALF) plus placebo tablet; FA group, subjects received PCS bread plus folic acid tablet (high-folate control).
a,b,cMean values within a row with unlike superscript letters were significantly different.
† Values for tablets represent folic acid content.
Table 4. Comparison of plasma folate (nmol/l), red-cell folate (nmol/l) and plasma homocyst(e)ine (mmol/l) during the stages of the intervention within and
between dietary groups
(Values are arithmetic means and their 95 % CI)
PCS group (n 25) ALF group (n 25) FA group (n 18)
Mean 95 % CI Mean 95 % CI Mean 95 % CI P (ANOVA)†
Plasma folate (nmol/l)
Baseline 12·7 10·5, 14·9 12·9 9·9, 15·7 17·5 13·2, 21·8 0·0618 (NS)
4 weeks 11·9 9·6, 14·3 21·6 17·5, 25·7*** 30·9 25·9, 35·9*** ,0·0001
8 weeks 11·7 9·0, 14·5 25·8 21·2, 30·4*** 35·9 31·7, 40·0*** ,0·0001
12 weeks 13·6 10·7, 16·3 25·0 20·7, 29·3*** 36·1 32·5, 39·6*** ,0·0001
16 weeks 13·6 10·8, 16·3 27·1 22·5, 31·7*** 40·1 35·0, 45·1*** , 0·0001
P (ANOVA)‡ 0·6373 NS ,0·0001 ,0·0001 ,0·0001 ,0·0001
Red-cell folate (nmol/l)
Baseline 497 414, 581 509 434, 584 572 438, 706 0·7768 (NS)
4 weeks 453 390, 516 538 477, 599 581 498, 663 0·0105
8 weeks 496 422, 469 637 557, 717 729 644, 815* ,0·0001
12 weeks 594 489, 700 803 693, 912*** 1025 909, 1142*** ,0·0001
16 weeks 578 481, 673 768 676, 860*** 999 881, 1118*** ,0·0001
P (ANOVA)‡ 0·0810 NS ,0·0001 ,0·0001 ,0·0001 ,0·0001
Plasma homocyst(e)ine (mmol/l)
Baseline 9·7 8·2, 11·1 9·1 8·2, 10·0 8·1 7·4, 8·9 0·1271 (NS)
4 weeks 9·3 7·5, 11·1 7·9 7·1, 8·7 6·5 5·7, 7·3* 0·0018
8 weeks 9·5 7·0, 11·9 6·8 6·3, 7·3*** 6·6 5·9, 7·3 0·0014
12 weeks 8·9 7·5, 10·4 7·1 6·3, 7·9** 6·5 5·6, 7·3* 0·0011
16 weeks 8·3 7·0, 9·6 6·8 6·2, 7·5*** 6·0 5·4, 6·6** 0·0008
P (ANOVA)‡ 0·5092 NS ,0·0001 ,0·0001 0·0017 0·0017
Treatment groups: PCS group, subjects received bread made with pericarp seed coat (PCS) flour plus placebo tablet (low-folate control); ALF group, subjects received bread made with
aleurone flour (ALF) plus placebo tablet; FA group, subjects received PCS bread plus folic acid tablet (high-folate control).
Mean values were significantly different for comparison against baseline within the same group: *P,0·05, **P,0·01, ***P,0·001.
† Comparison across groups based on log-transformed data.
‡ Comparison within group based on log-transformed data.
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chromosome breaks or lowering of homocyst(e)ine) of natural
folate (Cuskelly et al. 1996; Brouwer et al. 1999; Fenech,
2001; Melse-Boonstra et al. 2004). It is therefore important to
identify dietary sources that are naturally high in folate and
have a high bioavailability and bioefficacy relative to folic acid
supplementation.
Wheat aleurone flour is a novel food product that has the poten-
tial to make an important contribution to intake of natural folate.
The aleurone cells, together with the germ, contain the wheat
grain’s essential nutrients required for the growth and develop-
ment of the embryo (Saxelby & Venn-Brown, 1980; Clysedale,
1994). One of the most notable features of the composition of
this product is the high level of folate, which is present at a con-
centration .500mg/100 g wet ALF. This natural level of folate is
higher than that observed in wheat bran, fruits and vegetables
(usually between 20 and 200mg/100 g wet weight; Subar et al.
1989; Bailey, 1995) and is comparable to folate/folic acid levels
in fortified flour and cereal that provide 50 % of the RDA per ser-
ving (assuming an RDA of 400mg and a serving size of 40 g wet
weight; Crane et al. 1995). The results from the present study
show for the first time that moderate intake of ALF is an effective
strategy for raising red-cell folate and lowering plasma homocys-
t(e)ine in individuals who were selected for their relatively low
red-cell folate and relatively high plasma homocyst(e)ine.
It has previously been thought that bioavailability and bioeffi-
cacy of natural folate are strongly limited by polyglutamation.
However, there is a growing body of evidence indicating that cer-
tain natural sources of folate may have bioavailability and bioef-
ficacy values .50 % relative to that of synthetic folic acid. For
example, results from the present study can be compared with
those of Brouwer et al. (1999), who examined the effect
of increasing folate intake from a baseline of 210mg/d to
560mg/d, by controlled increased citrus fruit and vegetable
intakes over a 4-week period, on changes in plasma folate and
homocyst(e)ine. Their results showed an increase of 6·5 nmol/l
in plasma folate and a decrease of 1·5mmol/l in plasma homocys-
t(e)ine. The present study at 4 weeks showed an increase of
8·7 nmol/l in plasma folate and a decrease in plasma homocys-
t(e)ine of 1·2mmol/l in the ALF group, who had a higher intake
of folate (i.e. 836mg/d). From their results Brouwer et al.
(1999) estimated the bioavailability of folate from the vegetables
and citrus fruit relative to supplemental folic acid (250mg/d) to be
78 % based on plasma folate. A more recent study (Melse-Boon-
stra et al. 2004) determined the bioavailability and bioefficacy of
heptaglutamyl folate (one of the natural polyglutamated folate
forms commonly found in foods) relative to monoglutamyl
folate in men and women aged 50–75 years after 12 weeks at
daily supplement intake levels of 142 and 320mg, respectively.
These results showed that the bioavailability of heptaglutamyl
folic acid relative to monoglutamyl folic acid was 68 % on the
basis of red-cell folate and bioefficacy based on plasma homocys-
t(e)ine was 106 %.
Due to the relatively large differences between additional natu-
ral folate intake from bread in the ALF group relative to the FA
group (i.e. 404mg/d) and the additional folic acid intake from the
tablet in the FA group (608mg/d), and because intakes of folic
acid .400mg/d are likely to maximise the homocyst(e)ine-lower-
ing effect (van Oort et al. 2003), it was not possible to calculate
accurately the bioavailability and bioefficacy of ALF. Neverthe-
less, it is evident that a relatively small daily intake of ALF
bread (containing approximately 67 g ALF) can produce a homo-
cyst(e)ine-lowering effect that is of a similar magnitude to
that produced by a high-dose folic acid tablet supplement,
which suggests that natural folate in ALF has a high level of
bioavailability and bioefficacy. An earlier study, in which we
compared intake of 515mg natural folate from ALF and 500mg
folic acid in a tablet by measuring the area under the plasma
folate concentration v. time curve over a period of 7 h after con-
sumption, suggested that the bioavailability of folate from ALF
was similar to that of folic acid (Fenech et al. 1999). The decline
in plasma homocyst(e)ine in the ALF group (22·3mmol/l) is
greater than that observed in 50–70 year old men supplemented
with 700mg/d or 200mg/d folic acid (20·8mmol/l) and compar-
Fig. 2. Percentage change in (a) plasma folate, (b) red-cell folate and
(c) plasma homocyst(e)ine at 16 weeks relative to baseline. Percentage
change was adjusted for baseline value. FA, ALF and PCS refer to the treat-
ment groups: FA group, subjects (n 18) received bread made with pericarp
seed coat (PCS) flour plus folic acid tablet (high-folate control); ALF group,
subjects (n 25) received bread made with aleurone flour (ALF) plus placebo
tablet; PCS group, subjects (n 25) received PCS bread plus placebo tablet
(low-folate control). Values are means with standard errors shown by hori-
zontal bars. Mean values with unlike superscript letters were significantly
different by ANOVA: (a) P,0·0001, (b) P,0·0001, (c) P¼0·0034.
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able to that for young adults supplemented with 7mg/d vitamin
B12 and 700mg/d folic acid (22·7mmol/l) over a similar inter-
vention period (base-line plasma homocyst(e)ine was almost the
same between these studies, 9.1–9·4mmol/l) (Fenech et al.
1997, 1998). A meta-analysis of twelve clinical trials with folic
acid involving 1114 people estimated that supplementation with
folic acid (500–5000mg/d) should reduce plasma homocyst(e)ine
by 23 % in subjects who had folate (12 nmol/l) and homocys-
t(e)ine (12mmol/l) in plasma before treatment (Homocyst(e)ine
Lowering Trialists’ Collaboration, 1998). Subjects in the ALF
group in the present study had an additional natural folate
intake of 404mg/d from ALF, a pre-intervention plasma folate
of 12·9 nmol/l, a plasma homocyst(e)ine of 9·1mmol/l and a
25 % reduction (adjusted for baseline) in plasma homocyst(e)ine,
which is similar to the estimated effect for 500–5000mg folic
acid daily in the meta-analysis.
Mandatory fortification of flour with folic acid has proved to be
an effective and reliable method of preventing folate deficiency
and possibly diseases caused by folate deficiency such as neural
tube defects (Honein et al. 2001). It is clear from the results of
the present study that ALF has the potential to be a practical
alternative to folic acid fortification that may be useful in those
countries in which folic acid fortification is either not mandatory
or prohibited, and for those sections of the community who may
have a preference for eating natural sources of folate. ALF is also
a rich source of a wide range of vitamins, minerals and amino
acids required for cell growth and maintenance which may pro-
vide additional health benefits to those given by fortification
with folic acid alone (Hinton et al. 1953; Saxelby & Venn-
Brown, 1980). A direct comparison of ALF bread and bread
made with folic acid-fortified flour is required to determine the
relative performance of ALF bread for optimising folate status
as well as other measures of health status such as immune
response and genome stability. In the interim, the possibility of
inter-individual differences in deconjugation and absorption of
polyglutamated folate and the variation in folate content of
foods depending on cultivar, field conditions and method of prep-
aration should caution against relying solely on natural foods to
correct folate deficiency in the general population. In conclusion,
it is evident from the results of the present study that ALF is a
good source of bioavailable folate that can, at moderate intake
levels, increase tissue folate and reduce plasma homocyst(e)ine
substantially in man.
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